A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity
R Schroder,
KL Neuhaus,
A Leizorovicz,
T Linderer,
and
U Tebbe
Long-term mortality and morbidity of 1,741 patients with acute myocardial infarction, treated with intravenous streptokinase (1.5 million IU/h) or placebo, was assessed in a double-blind placebo-controlled trial (ISAM). At the 7 month follow-up, 94 (10.9%) of the 859 patients in the streptokinase group and 98 (11.1%) of the 882 patients in the placebo group had died; at an average follow-up of 21 months, 14.4% of the streptokinase group and 16.1% of the placebo group had died. The differences were not statistically significant. Long-term mortality was slightly higher in patients with anterior myocardial infarction and streptokinase treatment (20.1 versus 18.4%) and lower in patients with inferior myocardial infarction (10.2 versus 14.2%). Patients with previous myocardial infarction had a higher long-term mortality rate with streptokinase (34.9 versus 21.5% with placebo, p = 0.03). At 7 months, there were significantly more cases of reinfarction in the streptokinase group (7.2 versus 4.5%, p = 0.02). It is concluded that despite a significant limitation of infarct size by intravenous streptokinase, long-term mortality is only slightly reduced and reinfarction is significantly more frequent. Both findings suggest the need for complementary therapy such as revascularization procedures after thrombolysis.
This article has been cited by other articles:

|
 |

|
 |
 
C J Terkelsen, J F Lassen, B L Norgaard, J C Gerdes, T T Nielsen, and H R Andersen
Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction?
Heart,
May 1, 2003;
89(5):
483 - 484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Scrutinio, C. Cimminiello, E. Marubini, M. Vittoria Pitzalis, M. Di Biase, P. Rizzon, and the STAMI Group
Ticlopidine versus aspirin after myocardial infarction (stami) trial
J. Am. Coll. Cardiol.,
April 1, 2001;
37(5):
1259 - 1265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Franzosi, E. Santoro, C. De Vita, E. Geraci, A. Lotto, A. P. Maggioni, F. Mauri, F. Rovelli, L. Santoro, L. Tavazzi, et al.
Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction : Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study
Circulation,
December 15, 1998;
98(24):
2659 - 2665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Kuralay, U. Demirkilic, E. Ozal, F. Cingoz, H. Karaeren, and H. Tatar
Recovery of Left Ventricular Diastolic Function After Coronary Bypass Surgery
Asian Cardiovasc Thorac Ann,
December 1, 1998;
6(4):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Baigent, R. Collins, P. Appleby, S. Parish, P. Sleight, and R. Peto
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
BMJ,
May 2, 1998;
316(7141):
1337 - 1343.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Kellett and J. Clarke
Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction
Med Decis Making,
October 1, 1995;
15(4):
297 - 310.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Christensen, L. Ravn, S. E. Rasmussen, and H. T. Sorensen
The Effect of Streptokinase on Return to Work 18 Months After a First Myocardial Infarction
Angiology,
October 1, 1995;
46(10):
923 - 928.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Grines, K. F. Browne, J. Marco, D. Rothbaum, G. W. Stone, J. O'Keefe, P. Overlie, B. Donohue, N. Chelliah, G. C. Timmis, et al.
A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction
N. Engl. J. Med.,
March 11, 1993;
328(10):
673 - 679.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E Haber, T Quertermous, G. Matsueda, and M. Runge
Innovative approaches to plasminogen activator therapy
Science,
January 6, 1989;
243(4887):
51 - 56.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zatuchni
Letters to the Editor and Case Reports: Postthrombolytic High-Risk Syndrome
Angiology,
August 1, 1988;
39(8):
773 - 774.
[PDF]
|
 |
|
|